FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2533202009> ?p ?o ?g. }

• W2533202009 endingPage "428" @default.
• W2533202009 startingPage "421" @default.
• W2533202009 abstract "This study aimed to study whether cancer cells possess distinguishing metabolic features compared with surrounding normal cells, such as increased glutamine uptake. Given this, quantitative measures of glutamine uptake may reflect critical processes in oncology. Approximately, 10 % of patients with colorectal cancer (CRC) express BRAF V600E , which may be actionable with selective BRAF inhibitors or in combination with inhibitors of complementary signaling axes. Non-invasive and quantitative predictive measures of response to these targeted therapies remain poorly developed in this setting. The primary objective of this study was to explore 4-[18F]fluoroglutamine (4-[18F]F-GLN) positron emission tomography (PET) to predict response to BRAFV600E-targeted therapy in preclinical models of colon cancer. Tumor microarrays from patients with primary human colon cancers (n = 115) and CRC liver metastases (n = 111) were used to evaluate the prevalence of ASCT2, the primary glutamine transporter in oncology, by immunohistochemistry. Subsequently, 4-[18F]F-GLN PET was evaluated in mouse models of human BRAF V600E -expressing and BRAF wild-type CRC. Approximately 70 % of primary colon cancers and 53 % of metastases exhibited positive ASCT2 immunoreactivity, suggesting that [18F]4-F-GLN PET could be applicable to a majority of patients with colon cancer. ASCT2 expression was not associated selectively with the expression of mutant BRAF. Decreased 4-[18F]F-GLN predicted pharmacological response to single-agent BRAF and combination BRAF and PI3K/mTOR inhibition in BRAF V600E -mutant Colo-205 tumors. In contrast, a similar decrease was not observed in BRAF wild-type HCT-116 tumors, a setting where BRAFV600E-targeted therapies are ineffective. 4-[18F]F-GLN PET selectively reflected pharmacodynamic response to BRAF inhibition when compared with 2-deoxy-2[18F]fluoro-d-glucose PET, which was decreased non-specifically for all treated cohorts, regardless of downstream pathway inhibition. These findings illustrate the utility of non-invasive PET imaging measures of glutamine uptake to selectively predict response to BRAF-targeted therapy in colon cancer and may suggest further opportunities to inform colon cancer clinical trials using targeted therapies against MAPK activation." @default.
• W2533202009 created "2016-10-28" @default.
• W2533202009 creator A5028063270 @default.
• W2533202009 creator A5030600596 @default.
• W2533202009 creator A5042841835 @default.
• W2533202009 creator A5043300006 @default.
• W2533202009 creator A5062656698 @default.
• W2533202009 creator A5085028455 @default.
• W2533202009 creator A5087826096 @default.
• W2533202009 date "2016-10-21" @default.
• W2533202009 modified "2023-10-11" @default.
• W2533202009 title "Non-Invasive Glutamine PET Reflects Pharmacological Inhibition of BRAFV600E In Vivo" @default.
• W2533202009 cites W134122321 @default.
• W2533202009 cites W1589637684 @default.
• W2533202009 cites W1806952617 @default.
• W2533202009 cites W1844290099 @default.
• W2533202009 cites W1967717604 @default.
• W2533202009 cites W1975854213 @default.
• W2533202009 cites W2005616300 @default.
• W2533202009 cites W2014988241 @default.
• W2533202009 cites W2022101765 @default.
• W2533202009 cites W2034586537 @default.
• W2533202009 cites W2037679360 @default.
• W2533202009 cites W2039462497 @default.
• W2533202009 cites W2043508222 @default.
• W2533202009 cites W2052543023 @default.
• W2533202009 cites W2055255976 @default.
• W2533202009 cites W2056174640 @default.
• W2533202009 cites W2056843519 @default.
• W2533202009 cites W2065973001 @default.
• W2533202009 cites W2066800748 @default.
• W2533202009 cites W2066808338 @default.
• W2533202009 cites W2070371419 @default.
• W2533202009 cites W2074820129 @default.
• W2533202009 cites W2074873270 @default.
• W2533202009 cites W2086816631 @default.
• W2533202009 cites W2090406819 @default.
• W2533202009 cites W2098120709 @default.
• W2533202009 cites W2109236749 @default.
• W2533202009 cites W2113146100 @default.
• W2533202009 cites W2121691257 @default.
• W2533202009 cites W2123512807 @default.
• W2533202009 cites W2132117833 @default.
• W2533202009 cites W2137785594 @default.
• W2533202009 cites W2141517721 @default.
• W2533202009 cites W2149343603 @default.
• W2533202009 cites W2157230165 @default.
• W2533202009 cites W2239158335 @default.
• W2533202009 cites W2256545339 @default.
• W2533202009 cites W2262414037 @default.
• W2533202009 cites W2316444757 @default.
• W2533202009 cites W2345460318 @default.
• W2533202009 doi "https://doi.org/10.1007/s11307-016-1008-z" @default.
• W2533202009 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6476310" @default.
• W2533202009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27770401" @default.
• W2533202009 hasPublicationYear "2016" @default.
• W2533202009 type Work @default.
• W2533202009 sameAs 2533202009 @default.
• W2533202009 citedByCount "15" @default.
• W2533202009 countsByYear W25332020092017 @default.
• W2533202009 countsByYear W25332020092018 @default.
• W2533202009 countsByYear W25332020092019 @default.
• W2533202009 countsByYear W25332020092020 @default.
• W2533202009 countsByYear W25332020092021 @default.
• W2533202009 countsByYear W25332020092022 @default.
• W2533202009 countsByYear W25332020092023 @default.
• W2533202009 crossrefType "journal-article" @default.
• W2533202009 hasAuthorship W2533202009A5028063270 @default.
• W2533202009 hasAuthorship W2533202009A5030600596 @default.
• W2533202009 hasAuthorship W2533202009A5042841835 @default.
• W2533202009 hasAuthorship W2533202009A5043300006 @default.
• W2533202009 hasAuthorship W2533202009A5062656698 @default.
• W2533202009 hasAuthorship W2533202009A5085028455 @default.
• W2533202009 hasAuthorship W2533202009A5087826096 @default.
• W2533202009 hasBestOaLocation W25332020092 @default.
• W2533202009 hasConcept C121608353 @default.
• W2533202009 hasConcept C126322002 @default.
• W2533202009 hasConcept C142724271 @default.
• W2533202009 hasConcept C143998085 @default.
• W2533202009 hasConcept C150903083 @default.
• W2533202009 hasConcept C193270364 @default.
• W2533202009 hasConcept C204232928 @default.
• W2533202009 hasConcept C207001950 @default.
• W2533202009 hasConcept C2775842073 @default.
• W2533202009 hasConcept C2779013556 @default.
• W2533202009 hasConcept C2779349466 @default.
• W2533202009 hasConcept C2780283643 @default.
• W2533202009 hasConcept C2989005 @default.
• W2533202009 hasConcept C502942594 @default.
• W2533202009 hasConcept C515207424 @default.
• W2533202009 hasConcept C526805850 @default.
• W2533202009 hasConcept C55493867 @default.
• W2533202009 hasConcept C62478195 @default.
• W2533202009 hasConcept C71924100 @default.
• W2533202009 hasConcept C86554907 @default.
• W2533202009 hasConcept C86803240 @default.
• W2533202009 hasConceptScore W2533202009C121608353 @default.
• W2533202009 hasConceptScore W2533202009C126322002 @default.

• next